RTP Mobile Logo
Select Publications

Bose P, Verstovsek S. SOHO state of the art updates and next questions: Identifying and treating “progression” in myelofibrosis. Clin Lymphoma Myeloma Leuk 2021;21(10):641-9. Abstract

Chifotides HT et al. Momelotinib: An emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 2022;15(1):7. Abstract

Chifotides HT et al. SOHO state of the art updates and next questions: Novel therapies in development for myelofibrosis. Clin Lymphoma Myeloma Leuk 2021;[Online ahead of print]. Abstract

Gerds AT et al. Ruxolitinib re-treatment in patients with myelofibrosis: Real-world evidence on patient characteristics and outcomes. Acta Haematol 2022;1-5. Abstract

Gupta V et al. Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): Results from the phase 3b FREEDOM trial. ASH 2021;Abstract 389.

Harrison CN et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol 2022;[Online ahead of print]. Abstract

Kremyanskaya M et al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis – Update of clinical and translational data from the ongoing Manifest trial. ASH 2021;Abstract 141.

Mascarenhas J et al. Paradigm shift: Combination BET and JAK inhibition in myelofibrosis. Leukemia 2021;35(12):3361-3. Abstract

Mascarenhas J et al. A randomized open-label, phase 3 study to evaluate imetelstat versus best available therapy (BAT) in patients with intermediate-2 (Int-2) or high-risk myelofibrosis (MF) refractory to Janus kinase inhibitor (JAKi). ASH 2021;Abstract 1503.

Mesa RA et al. INDEPENDENCE: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions. ASH 2021;Abstract 1490.

Palmer JM et al. The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the Persist-2 study. ASH 2021;Abstract 3628.

Pemmaraju N et al. Immunotherapy and immunomodulation in myeloproliferative neoplasms. Hematol Oncol Clin North Am 2021;35(2):409-29. Abstract

Shahin OA et al. Accelerated phase of myeloproliferative neoplasms. Acta Haematol 2021;144(5):484-99. Abstract

Vachhani P et al. Disease modification in myelofibrosis: An elusive goal? J Clin Oncol 2022;[Online ahead of print]. Abstract

Verstovsek S et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: Impact of ruxolitinib approval. Ann Hematol 2022;101(1):131-7. Abstract

Verstovsek S et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the Comfort I and II studies. ASH 2021;Abstract 1505.

Verstovsek S et al. Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice. Leuk Res 2021;110:106711. Abstract

Verstovsek S et al. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica 2021;[Online ahead of print]. Abstract

Verstovsek S et al. Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data. ASH 2021;Abstract 2568.

Verstovsek S et al. MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021;17(12):1449-58. Abstract

Yacoub A et al. Subgroup analysis from a phase 2 study of the efficacy and safety of parsaclisib, a selective P13K-alpha inhibitor, in combination with ruxolitinib in patients with myelofibrosis. ASH 2021;Abstract 3647.

Yacoub A et al. A randomized, double-blind, placebo-controlled phase 3 study of add-on parsaclisib in patients with myelofibrosis who have suboptimal response to ruxolitinib. ASH 2021;Abstract 1502.

Yacoub A et al. A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment–naive myelofibrosis. ASH 2021;Abstract 2579.